Peptipedia
Growth HormoneNot FDA ApprovedAnimal Studies

Sermorelin

Also known as Geref, GRF 1-29

A truncated analog of natural GHRH containing the first 29 amino acids, used off-label for hormone optimization.

Previously FDA Approved (discontinued) - Off-label use continues
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

200-500 mcg before bed

Frequency

Once daily, before bed

Duration

3-6 months typical

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 200-500 mcg before bed via Subcutaneous injection at bedtime, Once daily, before bed. Dose range: 100-500 mcg daily. Duration: 3-6 months typical.

Timing & Administration

Administer via Subcutaneous injection at bedtime. Frequency: Once daily, before bed.

Mechanism of Action

Stimulates pituitary's natural GH production while maintaining normal feedback mechanisms and pulsatile release patterns.

Research Summary

Evidence level: animal studies. Clinical status: Previously FDA Approved (discontinued) - Off-label use continues.

Side Effects & Safety

Important Warnings

  • Take on empty stomach, at least 2 hours after last meal
Facial flushing
injection site reactions
headache
nausea
dizziness
joint pain
water retention
elevated IGF-1
allergic reactions

References

No references available.

Related Peptides

Browse all →
IpamorelinGrowth Hormone

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.

View profile
CJC-1295Growth Hormone

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary.

View profile
TesamorelinGrowth Hormone

An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

View profile